Form D · Pharmaceuticals
Cytogel Pharma, LLC
Darien, CT · CIK 0001491841
Offering snapshot reported Mar 26, 2026 · SEC filing
- Reported sold
- Yet to sell Offering amount: $16M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 26, 2026 | Amendment | Yet to sell | No comparison | 0 | SEC filing |
| Dec 23, 2025 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Dec 23, 2025 | Amendment | $250,000 | No comparison | 3 | SEC filing |
| Oct 11, 2024 | Amendment | $1,763,884 | $110,000vs Jul 28, 2023 | 18 | SEC filing |
| Jul 28, 2023 | Initial | $1,653,884 | No comparison | 15 | SEC filing |
| Jul 12, 2022 | Initial | $50,000 | No comparison | 1 | SEC filing |
| May 21, 2021 | Amendment | $956,905 | $281,550vs Mar 16, 2021 | 12 | SEC filing |
| Mar 16, 2021 | Amendment | $675,355 | $175,355vs Sep 30, 2019 | 10 | SEC filing |
| Mar 23, 2020 | Amendment | $575,000 | $75,000vs Sep 30, 2019 | 3 | SEC filing |
| Sep 30, 2019 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Mar 12, 2019 | Initial | $100,000 | No comparison | 3 | SEC filing |
| May 31, 2018 | Initial | $161,800 | No comparison | 5 | SEC filing |
| Jan 7, 2015 | Initial | $2,691,190 | No comparison | 10 | SEC filing |
| Mar 20, 2014 | Initial | $240,000 | No comparison | 2 | SEC filing |
| Jul 12, 2013 | Amendment | $750,000 | $734,525vs Feb 12, 2013 | 6 | SEC filing |
| Feb 12, 2013 | Initial | $15,475 | No comparison | 1 | SEC filing |
| May 17, 2010 | Initial | $2,200,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.12M (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-567842
The placement agent is entitled to a cash sales commission in an amount ranging from 2% to 7% of the aggregate amount of membership units sold depending upon the purchaser. The placement agent also is entitled to warrants.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| FDX Capital LLC | 000119302 | |
| XMS Capital Partners, LLC | 000142871 |
Source: Form D, filed Mar 26, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Aniello A. Bianco | Director |
| William M. Carello | Director, Executive |
| Steven Chrust | Director |
| Alan Dunton | Director |
| E. Bulkeley Girswold | Director |
| E. Bulkeley Griswold | Director |
| E. Bulkeley Griwold | Director |
| Cassandra Klimp | Director |
| Eric Lang | Director |
| Jerry P. Leamon | Director |
| C. Dean Maglaris | Director, Executive |
| Theodore Maione | Executive |
| Joseph J. Rucci | Director, Executive |
| Frederick W. Telling | Director, Executive |
| Michael Ullmann | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3 Thorndal Circle
Darien, CT, 06820
Phone: 203-966-9867
Darien, CT, 06820
Phone: 203-966-9867